financetom
Business
financetom
/
Business
/
JPMorgan Chase & Insider Sold Shares Worth $233,776,513, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan Chase & Insider Sold Shares Worth $233,776,513, According to a Recent SEC Filing
Feb 21, 2025 1:18 AM

04:01 AM EST, 02/21/2025 (MT Newswires) -- James Dimon, Director, Chairman & Chief Executive Officer, on February 20, 2025, sold 866,361 shares in JPMorgan Chase ( JPM ) & (JPM) for $233,776,513. Following the Form 4 filing with the SEC, Dimon has control over a total of 1,720,482 common shares of the company, with 1,322,150 shares held directly and 398,332 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/19617/000122520825002092/xslF345X05/doc4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Arc Document Solutions And Members Of Company Management Announce Definitive Merger Agreement
BRIEF-Arc Document Solutions And Members Of Company Management Announce Definitive Merger Agreement
Aug 29, 2024
Aug 28 (Reuters) - ARC Document Solutions Inc ( ARC ): * ARC DOCUMENT SOLUTIONS INC ( ARC ): CO AND MEMBERS OF COMPANY MANAGEMENT ANNOUNCE DEFINITIVE MERGER AGREEMENT * ARC DOCUMENT SOLUTIONS ( ARC ): POST AGREEMENT CO WILL MERGE WITH AND INTO TECHPRINT MERGER SUB, INC., UNIT OF TECHPRINT HOLDINGS, LLC * ARC DOCUMENT SOLUTIONS ( ARC ):...
AC Immune's Partner Life Molecular Gets FDA Fast Track Designation for PET Imaging Agent
AC Immune's Partner Life Molecular Gets FDA Fast Track Designation for PET Imaging Agent
Aug 29, 2024
09:41 AM EDT, 08/28/2024 (MT Newswires) -- AC Immune ( ACIU ) said Wednesday that the US Food and Drug Administration has issued a Fast Track Designation for the PI-2620 Tau positron emission tomography, or PET, imaging agent that the company is developing with privately held Life Molecular Imaging to diagnose three neurodegenerative conditions, including Alzheimer's disease. The Fast Track...
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Aug 29, 2024
Wednesday, Novartis AG ( NVS ) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention. Also Read: Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal. Leqvio monotherapy achieved...
Safe Pro Group Prices $5.1 Million IPO
Safe Pro Group Prices $5.1 Million IPO
Aug 29, 2024
09:32 AM EDT, 08/28/2024 (MT Newswires) -- Safe Pro Group (SPAI) said Wednesday that it has priced an initial public offering of 1.02 million shares at $5 per share for gross proceeds of $5.1 million, including underwriting discounts and other expenses. The drone-based technology company said underwriters have been granted a 45-day option to buy up to about 153,000 additional...
Copyright 2023-2026 - www.financetom.com All Rights Reserved